AVITA Medical Inc

AVITA Medical is a therapeutic acute wound care company focused on delivering technologies that optimize wound healing and accelerate patient recovery. Its flagship product, RECELL, is FDA-approved for the treatment of thermal burn and trauma wounds and uses a patient's own skin cells to create Spray-On Skin at the point of care. The company also holds exclusive U.S. rights to market Cohealyx, a collagen-based dermal matrix, and to manufacture, market, and distribute PermeaDerm, a biosynthetic wound matrix used as an alternative to allograft for temporarily stabilizing and protecting wounds before definitive closure. Internationally, RECELL and RECELL GO are approved in multiple markets including Europe (CE-marked), Australia (TGA-certified), New Zealand (Medsafe-listed), and Japan (PMDA-approved) for a wide range of wound healing applications. The company is listed on both NASDAQ (RCEL) and the ASX (AVH) and is in a pre-profitability growth stage, with a commercial strategy centered on expanding physician adoption and utilization across its acute wound care portfolio. Updated Aug 6, 2026